Results 41 to 50 of about 178,855,135 (215)

Alterations of bone proteins in medication‐related osteonecrosis of the jaw

European Journal of Oral Sciences, Volume 133, Issue 2, April 2025.
Abstract Changes in the protein expression pattern of osteoblastic lineage cells from the alveolar bone (OLAB) during medication‐related osteonecrosis of the jaw (MRONJ) have rarely been investigated. This lack of information is partly because of the limited availability of healthy samples and the lack of human alveolar bone cell lines for research ...
Andrea Schubert, Phillipp Brockmeyer, Philipp Kauffmann, Jan Wiegel, Florian Lautenbacher, Nicolai Miosge, Boris Schminke   +6 more
wiley   +1 more source

Questionnaire about Occurrence and Condition of Bisphosphonate-Related Osteonecrosis of the Jaw [PDF]

, 2010
The purpose of this study was to survey the occurrence and condition of bisphosphonate-related osteonecrosis of the jaw (BRONJ). A questionnaire inquiring about clinical experience and the condition of patientswith BRONJ was sent to 11 departments of ...
鎌田, 孝広, 栗田, 浩, 盛岡, 昌史   +2 more
core   +1 more source

Drug assumption and awareness about adverse drug reactions. The right to know. The case of the bone-modyfing agents: a systematic review

Frontiers in Oral Health
IntroductionMedication-related osteonecrosis of the Jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to BMA and AA therapies, causing the progressive destruction and death of bone.
Rodolfo Mauceri, Rodolfo Mauceri, Sonia Arduini, Martina Coppini, Martina Coppini, Martina Coppini, Monica Bazzano, Isabel Trujillo, Giuseppina Campisi   +8 more
doaj   +1 more source

Bisphosphonate-associated jaw osteonecrosis in the treatment of rheumatoid arthritis [PDF]

RGO: Revista Gaúcha de Odontologia
This literature review aimed to raise the relationship between rheumatoid arthritis and mandibular osteonecrosis associated with bisphosphonates. The articles were collected in Pubmed, Bireme, Cochrane and Scielo between the years 2000 and 2023, the ...
Gabriela Dias Rosso dos Santos, Luciana Corrêa, Danielle Lima Corrêa de Carvalho   +2 more
doaj   +1 more source

Denosumab discontinuation and fracture risk: getting the balance right

Internal Medicine Journal, EarlyView.
Abstract Denosumab is a highly effective therapy for osteoporosis. Since its approval by the Therapeutic Goods Administration (TGA) in 2010, use of denosumab has surged across Australia, delivering substantial fracture‐prevention benefits to tens of thousands of patients. However, stopping denosumab may lead to acute loss of bone with an increased risk
Albert S. Kim, Christian M. Girgis
wiley   +1 more source

Cuidados na avaliação e atendimento odontológico em pacientes usuários de bisfosfonatos: uma revisão de literatura. [PDF]

, 2012
TCC (graduação) - Universidade Federal de Santa Catarina. Centro de Ciências da Saúde. Odontologia.Os bisfosfonatos são análogos estruturais do pirofosfato, que apresentam elevada afinidade pelo tecido ósseo.
Dengo, Suhéllen Vicenzi
core  

The Use of Imaging Methods in the Diagnosis of Bisphosphonate-related Osteonecrosis of the Jaw

, 2012
Objectives: Osteonecrosis of the jaws is a rare side effect of bisphosphonate therapy, occurring especially in oncological patients but also in patients with metabolic bone diseases.
L. Hostička, J. Baxa, L. Hauer, D. Hrušák, P. Andrle   +4 more
core   +1 more source

Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking

Journal of Applied Oral Science, 2015
Objective There is strong evidence of a link between the use of systemic bisphosphonates (BPs) and osteonecrosis of the jaw, especially in cancer patients.
Arezo TARDAST, Reine SJÖMAN, Sigbjørn LØES, Jahan ABTAHI   +3 more
doaj   +1 more source

The awareness and practice of dentists regarding medication-related osteonecrosis of the jaw and its prevention: a cross-sectional survey

BMC Oral Health, 2021
Background Accurate documentation of a patient’s prior medication use and awareness of side effects associated with anti-osteoporotic agents can assist dentists to prevent medication-related osteonecrosis of the jaw. I aimed to determine the awareness of
A. Lum Han
doaj   +1 more source

Imaging in Patients with Bisphosphonate-Associated Osteonecrosis of the Jaws (MRONJ) [PDF]

Dentistry Journal, 2016
Background: Bisphosphonate-associated osteonecrosis of the jaws (MRONJ/BP-ONJ/BRONJ) is a commonly seen disease. During recent decades, major advances in diagnostics have occurred. Once the clinical picture shows typical MRONJ features, imaging is necessary to determine the size of the lesion.
Berg, Britt-Isabelle, Mueller, Andreas A., Augello, Marcello, Berg, Scott, Jaquiéry, Claude   +4 more
openaire   +6 more sources